Johnson & Johnson $JNJ Stock Position Cut by Miller Investment Management LP

Miller Investment Management LP decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 39.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,859 shares of the company’s stock after selling 8,445 shares during the period. Miller Investment Management LP’s holdings in Johnson & Johnson were worth $2,384,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in JNJ. SOA Wealth Advisors LLC. lifted its position in Johnson & Johnson by 0.7% in the third quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock worth $1,371,000 after purchasing an additional 53 shares during the period. Ethos Financial Group LLC raised its stake in shares of Johnson & Johnson by 0.6% in the 3rd quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock worth $1,689,000 after buying an additional 53 shares in the last quarter. Heritage Oak Wealth Advisors LLC lifted its holdings in shares of Johnson & Johnson by 3.5% in the third quarter. Heritage Oak Wealth Advisors LLC now owns 1,639 shares of the company’s stock valued at $304,000 after buying an additional 55 shares during the period. Investor s Fiduciary Advisor Network LLC boosted its stake in Johnson & Johnson by 0.8% during the third quarter. Investor s Fiduciary Advisor Network LLC now owns 6,905 shares of the company’s stock valued at $1,280,000 after buying an additional 55 shares in the last quarter. Finally, TPG Advisors LLC boosted its stake in Johnson & Johnson by 3.5% during the third quarter. TPG Advisors LLC now owns 1,628 shares of the company’s stock valued at $302,000 after buying an additional 55 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,598,700.17. The trade was a 21.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the sale, the executive vice president directly owned 26,769 shares of the company’s stock, valued at $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 30,142 shares of company stock worth $7,360,528 over the last three months. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $245.53 on Tuesday. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $246.96. The firm’s 50 day simple moving average is $221.69 and its 200-day simple moving average is $199.96. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The company has a market cap of $591.70 billion, a P/E ratio of 22.22, a price-to-earnings-growth ratio of 2.35 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The firm had revenue of $24.28 billion during the quarter. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s payout ratio is currently 47.06%.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research analyst reports. Sanford C. Bernstein upped their price target on shares of Johnson & Johnson from $208.00 to $225.00 and gave the company a “market perform” rating in a report on Friday, January 23rd. Rothschild & Co Redburn boosted their target price on shares of Johnson & Johnson from $180.00 to $210.00 and gave the stock a “neutral” rating in a report on Thursday, February 19th. HSBC increased their target price on shares of Johnson & Johnson from $240.00 to $265.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Royal Bank Of Canada lifted their price target on shares of Johnson & Johnson from $240.00 to $255.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. Finally, Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $232.70.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Company momentum from product mix and recent earnings beat — analysts and commentators point to rising oncology revenues, a MedTech recovery and an earnings surprise as drivers of upside for JNJ. Read More.
• Positive Sentiment: Potential major asset sale — reports say Johnson & Johnson is exploring a sale of its orthopedics unit DePuy Synthes as part of a planned separation; a successful divestiture could unlock cash/value and simplify the company. Read More.
• Positive Sentiment: Clinical data supports Pharma franchise — J&J presented three‑year TREMFYA ulcerative colitis data showing sustained outcomes, which supports longer‑term revenue prospects for immunology assets. Read More.
• Positive Sentiment: Dividend and income appeal remain intact — JNJ’s regular dividend (recently announced/ex‑dividend timing noted in filings) keeps the stock attractive to income and long‑term investors. Read More.
• Neutral Sentiment: Market reports highlight structural tailwinds in vision and cataract devices — sector growth forecasts (phaco systems, femtosecond lasers) could benefit J&J’s device franchises over time but are longer‑term drivers. Read More.
• Neutral Sentiment: Strategic partnerships and analyst noise — a first co‑funding agreement with Blackstone and mixed analyst notes/option activity are being watched but have produced muted immediate market reaction. Read More.
• Negative Sentiment: Bayer lawsuit raises litigation overhang — Bayer sued J&J and Janssen in New York over claims around its Nubeqa prostate‑cancer drug, creating potential legal costs, distraction and uncertainty for Janssen’s oncology positioning. Read More.
• Negative Sentiment: Insider selling disclosed — EVP Timothy Schmid filed a sale of 1,322 shares (additional prior sales also disclosed); routine but may be viewed by some investors as profit‑taking. Read More.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.